# CJC-1295 and Ipamorelin: What FDA Recorded

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-08-16 | Updated: 2026-11-06

Canonical page: https://glpwatchdog.org/research/cjc-1295-ipamorelin-stack

> Sold as a stack for fat loss. FDA identified serious adverse events with CJC-1295 (increased heart rate and systemic vasodilatory reaction), and neither peptide has a weight-loss trial.

## Key points

- Ipamorelin acetate is in FDA’s ACTIVE category 2 for 503B compounding, added September 29, 2023.
- CJC-1295 was nominated for the 503A list and withdrawn, and FDA named serious adverse events: increased heart rate and systemic vasodilatory reaction.
- FDA on CJC-1295: “Available clinical data are limited.”
- The best human trial ipamorelin has was not about weight at all. It studied POSTOPERATIVE ILEUS.

[CJC-1295 and ipamorelin](https://glpwatchdog.org/peptides/cjc-1295-ipamorelin) are sold together, usually as a “stack”, on the theory that one extends a growth hormone pulse while the other triggers it. Both are flagged in FDA’s compounding safety records, and one of them carries language stronger than FDA used for most other peptides in this market: **“serious adverse events… including increased heart rate and systemic vasodilatory reaction.”**[1]

Neither is approved for anything, and neither has been tested for weight loss. The human trial data that exist measured hormone levels or treated an entirely unrelated condition.

## Where each one actually sits

*FDA compounding status, verified from the agency's own tables*

|   | CJC-1295 | Ipamorelin acetate |
| --- | --- | --- |
| FDA listing | Nominated for the 503A list, then withdrawn | **Active category 2** under 503B, added September 29, 2023, and separately withdrawn from its 503A nomination |
| Immunogenicity | Flagged for certain routes of administration | Flagged, from potential aggregation or peptide-related impurities |
| Characterization | Complexities with impurities and identifying the active ingredient | Contains **unnatural amino acids**, adding complexity to characterization |
| Adverse events | **Serious events named in the entry: a raised heart rate, and a systemic vasodilatory reaction** | Serious adverse events, including death, from a published study of intravenous use for gastric motility |
| Clinical data | “Available clinical data are limited.” | — |

> “FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction. Available clinical data are limited.”[1]
>
> — FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks

> **That is stronger than what FDA wrote about BPC-157**, where the finding was an absence of information rather than identified events. Here the agency is naming two specific cardiovascular effects. “Systemic vasodilatory reaction” means blood vessels dilating body-wide. That drops blood pressure, and the raised heart rate is what compensates for it.

FDA’s 2024 briefing says CJC-1295’s developer withdrew the DAC form from clinical trials in 2006 after a phase 2 participant died.[7] FDA calls its sources for the details anecdotal. They describe a person with HIV lipodystrophy who had chest discomfort about two hours after an 11th weekly dose, an ECG-confirmed heart attack, and death about an hour later. The attending physician’s leading explanation was undiagnosed coronary artery disease, so this does not show the drug caused the death. The trial’s data were never published.[7]

## The theory behind stacking them

The two act on different receptors, which is the whole argument for combining them. CJC-1295 is a growth hormone-releasing hormone analog engineered for a long half-life. Ipamorelin is a ghrelin mimetic, described in the literature as the first *selective* growth hormone secretagogue, meaning it raises GH without the cortisol and prolactin rises that made earlier compounds in its class unattractive.[2] That selectivity was shown in pigs; how it compares with the older [hexarelin](https://glpwatchdog.org/research/hexarelin-what-the-evidence-shows), whose cortisol rise was measured in people, is set out separately.

That pharmacology is real. CJC-1295 does produce prolonged elevation of growth hormone and IGF-I in humans, which is what the 2006 trial measured.[3] The gap is what comes next: raising a hormone is not the same as producing a clinical result, and the second step has not been tested.

## What the human trials actually studied

- **CJC-1295, 2006.** Prolonged stimulation of GH and IGF-I secretion in humans. An endocrine measurement study, not a weight or body-composition trial.[3]
- **Ipamorelin, 1998.** The original characterization paper establishing it as a selective GH secretagogue.[2]
- **Ipamorelin, 1999.** Pharmacokinetic and pharmacodynamic modeling in human volunteers.[4]
- **Ipamorelin, 2014.** A randomized, controlled proof-of-concept study for the management of **postoperative ileus**, a bowel-motility problem after surgery.[5] Nothing to do with weight.

> **The last trial on that list is the one to notice.** The most rigorous human trial of ipamorelin was randomized and controlled, and it was run in surgical patients to see whether their bowels would start working again sooner. That is what the strongest evidence for this peptide is about. It is being sold to you for fat loss.

## Against what the sellers list beside it

On the same menu you will typically find compounded semaglutide or tirzepatide. Those molecules have phase 3 trials with thousands of participants and body weight as the primary endpoint. This pair has hormone-level studies and an ileus trial.

The pairing is easy to find in our register. [Dr. Gillis’ Wellness Center](https://glpwatchdog.org/reviews/dr-gillis-wellness-center), [Live Vital](https://glpwatchdog.org/reviews/live-vital) and [DrBrainRx](https://glpwatchdog.org/reviews/drbrainrx) list CJC-1295 with ipamorelin beside semaglutide and tirzepatide, and so do [RxPepsDirect](https://glpwatchdog.org/reviews/rxpepsdirect), [ElitePhysiqMD](https://glpwatchdog.org/reviews/elitephysiqmd) and [Iron Med RX](https://glpwatchdog.org/reviews/iron-med-rx). [Thriving Again](https://glpwatchdog.org/reviews/thriving-again) and [TeleCareSpot](https://glpwatchdog.org/reviews/telecarespot) list ipamorelin on its own next to their GLP-1 programs. Iron Med RX and TeleCareSpot do not name the pharmacy that fills their orders, which makes the second question below harder to answer before you buy.

None of this says growth hormone does nothing. It demonstrably affects body composition in people who are deficient in it. The question is what has been demonstrated in people who are not. The same gap runs through [sermorelin](https://glpwatchdog.org/research/sermorelin-for-weight-loss), which does have an approval history and has no weight-loss trial either. How the two peptides in the stack differ from each other is in [CJC-1295 vs ipamorelin](https://glpwatchdog.org/research/cjc-1295-vs-ipamorelin), and CJC-1295 on its own, including FDA’s 2024 advisory vote on it, has its own [CJC-1295 profile](https://glpwatchdog.org/peptides/cjc-1295). The public catalog at [System Labs](https://glpwatchdog.org/reviews/system-labs) lists sermorelin as an injection or a tablet, and neither CJC-1295 nor ipamorelin.

## If you are being offered the stack

1. **Ask about the cardiovascular effects by name.** FDA identified increased heart rate and systemic vasodilatory reaction with CJC-1295. A seller offering it should be able to discuss that rather than hear it from you.
2. **Ask which pharmacy compounds it and under what authority**, given that ipamorelin is in active category 2 for 503B and CJC-1295 is on neither list. Neither is among the six peptides in HHS’s interim enforcement-discretion policy of October 28, 2026, and that policy covers single-ingredient products only, so a combined stack falls outside it in any case.[6]
3. **Ask for the weight-loss trial.** Not a mechanism and not a case series, but the trial itself. Notice what arrives instead.
4. **Ask what it adds to the GLP-1 you are already paying for**, and what that addition costs per month.

## Common questions

## Frequently asked questions

### Is CJC-1295 with ipamorelin FDA-approved?

No. Neither is approved for any condition. Ipamorelin acetate is in FDA's active category 2 for 503B compounding (substances that may present significant safety risks), added September 29, 2023. CJC-1295 was nominated for the 503A list and withdrawn. Neither is covered by the interim policy HHS announced on October 28, 2026, under which HHS does not intend to take enforcement action against 503A pharmacies that compound six other peptides, including BPC-157 and TB-500, under strict conditions.

### What are the risks of CJC-1295?

Two are named in the agency's own entry, quoted above: a raised heart rate, and a systemic vasodilatory reaction. FDA calls these serious, and adds that the clinical data available on the peptide are limited. That is more specific than what the agency wrote about most peptides in this market, where the finding is usually an absence of information rather than identified events.

### Does the stack cause weight loss?

No trial has tested that. Both peptides raise growth hormone, which is measurable and real. Whether that produces weight loss in adults with normal growth hormone levels is the question nobody has run a study on, and a mechanism is not a result.

### Why combine two peptides?

They act on different receptors. CJC-1295 is a growth hormone-releasing hormone analog with an extended half-life and ipamorelin is a selective ghrelin mimetic, so the theory is that one sustains what the other triggers. The pharmacological logic is coherent. It is the clinical outcome that is untested.

### Is ipamorelin safer than CJC-1295?

FDA's entries differ, which is not the same as one being safe. Ipamorelin's concerns are immunogenicity from aggregation or impurities, plus unnatural amino acids that complicate characterizing what is in a vial, and it cites serious adverse events, including death, in a published study of intravenous use. CJC-1295's entry names adverse events FDA itself identified, and FDA's 2024 briefing describes anecdotal reports of a 2006 trial death, which the attending physician attributed to coronary artery disease. Neither is a clean bill of health.

### Can I take this alongside a GLP-1?

That is a question for a prescriber who knows your history, and one worth asking properly rather than assuming, particularly given the cardiovascular effects FDA has recorded for CJC-1295. Whatever you decide, your prescriber should know everything you are injecting.

## References

1. U.S. Food and Drug Administration Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — entries for CJC-1295 and Ipamorelin acetate. FDA Human Drug Compounding. 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
2. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PMID: 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/
3. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
4. Gobburu JV, Agersø H, Jusko WJ Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999. PMID: 10496658. https://pubmed.ncbi.nlm.nih.gov/10496658/
5. Beck DE, Sweeney WB, McCarter MD Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus. Int J Colorectal Dis. 2014. PMID: 25331030. https://pubmed.ncbi.nlm.nih.gov/25331030/
6. U.S. Department of Health and Human Services HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (with Appendices A and B), announced October 28, 2026. HHS. 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
7. U.S. Food and Drug Administration FDA Briefing Document for CJC-1295 Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee, December 4, 2024. FDA. 2024. https://www.fda.gov/media/183819/download

---

Cite as: GLP Watchdog, Ruth Calder, "CJC-1295 and Ipamorelin: What FDA Recorded", published 2026-08-16, updated 2026-11-06. https://glpwatchdog.org/research/cjc-1295-ipamorelin-stack

Canonical HTML page: https://glpwatchdog.org/research/cjc-1295-ipamorelin-stack

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
